<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04174599</url>
  </required_header>
  <id_info>
    <org_study_id>SP11631</org_study_id>
    <nct_id>NCT04174599</nct_id>
  </id_info>
  <brief_title>Trial to Compare the Efficacy and Safety of F-627 and GRAN®</brief_title>
  <acronym>F-627</acronym>
  <official_title>A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Trial to Compare the Efficacy and Safety of F-627 and GRAN® in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Generon (Shanghai) Corporation Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Generon (Shanghai) Corporation Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Trial to Compare the
      Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion
      Protein (F-627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the
      Prophylactic Treatment for Chemotherapy-Induced Neutropenia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol Number: SP11631 Study Stage: Phase III Study Population Female patients with breast
      cancer will be enrolled to receive at least 4 cycles of EC chemotherapy, that is: epirubicin
      100 mg/m2 and cyclophosphamide 600 mg/m2.

      Study Design: A multi-center, randomized, open-label, active-controlled phase III clinical
      trial Site Number: 14 sites(planned) , 12 sites(actual) Subject Number: 240
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2018</start_date>
  <completion_date type="Actual">June 19, 2019</completion_date>
  <primary_completion_date type="Actual">January 24, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of F-627 versus GRAN® in the first cycle of prophylactic treatment in subjects with breast cancer receiving chemotherapy, as assessed by the number of days in which ANC &lt; 1.0 × 109/L in cycle 1</measure>
    <time_frame>At the end of cycle 1（each cycle is 21 days）.</time_frame>
    <description>The primary endpoint is the duration (days) of grade 3 or 4 (moderate and severe) neutropenia in cycle 1, that is, the number of days in which ANC &lt; 1.0 × 109/L in cycle 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of grade 3 or 4 neutropenia as assessed by ANC（ANC &lt; 1.0 × 109/L and ANC &lt; 0.5 × 109/L, respectively）</measure>
    <time_frame>through study completion, an average of 21 days.</time_frame>
    <description>The incidence rate of grade 3 or 4 neutropenia (ANC &lt; 1.0 × 109/L and ANC&lt; 0.5 × 109/L, respectively)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>durations (days) of grade 3 or 4 neutropenia as assessed by ANC（ANC &lt; 1.0 × 109/L and ANC &lt; 0.5 × 109/L, respectively）</measure>
    <time_frame>in cycles 2-4, at the end of cycle 4（each cycle is 21 days.）</time_frame>
    <description>The durations (days) of grade 3 or 4 neutropenia (ANC &lt; 1.0 × 109/L and &lt; 0.5 × 109/L, respectively)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence and duration (days) of grade 4 neutropenia are all as assessed by ANC（ANC &lt; 0.5 × 109/L）</measure>
    <time_frame>through study completion, an average of 21 days.</time_frame>
    <description>The incidence and duration (days) of grade 4 neutropenia (ANC &lt; 0.5 × 109/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall duration (days) of grade 3 or 4 neutropenia as assessed by ANC（ANC &lt; 1.0 × 109/L and ANC &lt; 0.5 ×109/L, respectively）</measure>
    <time_frame>through study completion, in overall 4 cycles（each cycle is 21 days）.</time_frame>
    <description>The overall duration (days) of grade 3 or 4 neutropenia (ANC &lt; 1.0 × 109/L and ANC&lt; 0.5 × 109/L, respectively)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and duration (days) of grade 2 or above neutropenia are all assessed by ANC (ANC &lt; 1.5 × 109/L)</measure>
    <time_frame>through study completion, an average of 21 days.</time_frame>
    <description>The incidence and duration (days) of grade 2 or above neutropenia (ANC &lt; 1.5 × 109/L) in each cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of febrile neutropenia (FN) (defined as ANC &lt; 1.0×109/L; a single measurement of body temperature &gt; 38.3°C or a temperature ≥ 38.0 °C sustained over 1 h)</measure>
    <time_frame>8 months</time_frame>
    <description>Incidence rate of febrile neutropenia (FN) (defined as ANC &lt; 1.0×109/L; a single measurement of body temperature &gt; 38.3 °C or a temperature ≥ 38.0 °C sustained over 1 hr)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANC nadir</measure>
    <time_frame>through study completion, an average of 21 days.</time_frame>
    <description>The time (days) of ANC nadir recovers to 2.0 × 109/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The neutrophil count nadir from day 3 to day 13 of cycle 1</measure>
    <time_frame>day 3 to day 13 of cycle 1（each cycle is 21 days）.</time_frame>
    <description>The ANC nadir from day 3 to day 13 of cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the time（days）of ANC nadir returns to 2.0 × 109/L</measure>
    <time_frame>through study completion, an average of 21 days.</time_frame>
    <description>The time (days) of ANC nadir recovers to 2.0 × 109/L</description>
  </secondary_outcome>
  <other_outcome>
    <measure>the potential immunogenicity of F-627 by testing anti-F-627 antibodies inserum</measure>
    <time_frame>8 months</time_frame>
    <description>To evaluate the immunogenic potential of F-627 by testing serum anti-F-627 antibodies.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>F-627</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive F-627 (20 mg/dose, s.c.) on day 3 of each cycle, i.e., 48 ±4 h after the start of chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GRAN®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive GRAN® [5 μg/kg/day, s.c., once daily (± 4 h) up to 2 weeks or until neutrophil count returns to 5.0 ×109/L] on day 3 of each cycle, i.e., 48 ±4 h after the start of chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>F-627</intervention_name>
    <description>Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein</description>
    <arm_group_label>F-627</arm_group_label>
    <arm_group_label>GRAN®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing to sign the informed consent form and able to comply with protocol
             requirements;

          2. 18-75 years old;

          3. Female postoperative patients with breast cancer who require adjuvant chemotherapy,
             and are planned to receive at least 4 cycles of EC chemotherapy, namely epirubicin 100
             mg/m2 + cyclophosphamide 600 mg/m2;

          4. ECOG performance status ≤ 2;

          5. Absolute neutrophil count (ANC) ≥ 2.0 × 109/L, hemoglobin (Hb) ≥ 11.0 g/dL, and
             platelet (PLT) ≥ 100 × 109/L prior to enrollment;

          6. Hepatic and renal functions: Total bilirubin ≤ 1.5 × ULN, ALT and AST ≤ 2.5 × ULN,
             serum creatinine ≤ 1.5 × ULN;

          7. Left ventricular ejection fraction &gt; 50%;

          8. Women without child-bearing potential, i.e., women who have had menopause for at least
             1 year or who have undergone sterilization (bilateral tubal ligation, double
             oophorectomy or hysterectomy); patients with child-bearing potential should agree to
             take appropriate contraceptive measures, including condoms, spermicidal condoms,
             foams, gels, contraceptive barrier, intrauterine devices (IUD), and contraceptives
             (oral or injection), starting from 1 month before the start of the study until 30 days
             after the end of the study.

        Exclusion Criteria:

          1. Radiation therapy within 4 weeks prior to enrollment;

          2. Patients with breast cancer who have received neoadjuvant chemotherapy before surgery;

          3. Prior bone marrow or stem cell transplant;

          4. With other malignant tumors other than breast cancer;

          5. Patients who have received a treatment with recombinant human granulocyte colony
             stimulating factor within 6 weeks prior to randomization;

          6. Diagnosed with acute congestive heart failure, cardiomyopathy, or myocardial
             infarction by clinical diagnosis, ECG or other approaches;

          7. With any disease that may cause splenomegaly;

          8. With acute infection, chronic active Hepatitis B within 1 year (unless patients tested
             negative for HBsAg prior to enrollment), or Hepatitis C;

          9. Women in pregnancy or breastfeeding;

         10. Known HIV positive or AIDS;

         11. With active tuberculosis (TB); history of TB exposure, unless negative for tuberculin
             test; TB patients undergoing treatment; or suspected TB evaluated by chest x-ray;

         12. With sickle cell anemia;

         13. With alcohol or drug abuse that may affect the compliance with the study;

         14. With known hypersensitivity to granulocyte colony stimulating factor or excipients;

         15. Have received any other investigational drug within 1 month or 5 half-lives of the
             investigational drugs prior to enrollment (whichever is longer);

         16. Patients with diseases or symptoms unsuitable for participating in the trial. For
             example, the study drugs may compromise the health of the patient or the assessment of
             adverse events may be affected.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female postoperative patients with breast cancer who require adjuvant chemotherapy, and are planned to receive at least 4 cycles of EC chemotherapy, namely epirubicin 100 mg/m2 + cyclophosphamide 600 mg/m2;</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhimin Shao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University Shanghai Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Peking</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

